Sandoz Launches Adalimumab Biosimilar in Canada
The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.
Sandoz Canada said it has launched low-concentration forms of an adalimumab injectable biosimilar (Hyrimoz), which is indicated for 9 of the 12 conditions of the originator product (Humira), including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, hidradenitis suppurativa, psoriasis, and adult uveitis.
As of late 2020, Health Canada had approved 35 biosimilars for marketing in the country, according to Sandoz. Grassroots efforts by regulators and health authorities in provinces and territories of Canada are rapidly advancing the use of biosimilars as a cost-savings measure and to free capital for the expansion of care to serve other needs.
The Ontario Drug Policy Research Network estimated that nonmedical and mandatory switching policies in all provinces for etanercept and infliximab biosimilars could have generated $239.6 million in national savings in 2019. The market for adalimumab in Canada is estimated at 42,000 patients.
Adalimumab is a tumor necrosis factor blocker that reduces inflammation. Sandoz said the product will be offered in 40-mg/0.8 mL and 20-mg/0.4mL doses in single-use prefilled syringes and in a 40-mg/0.8 mL dose in the SensoReady pen autoinjector, designed for patients with limited dexterity.
Authorization for the marketing of Hyrimoz was issued by Health Canada in December 2020. The approval marked the fourth biosimilar approval in Canada in 11 months for Sandoz, whose biosimilars portfolio in Canada now encompasses oncology, immunology, and endocrinology products.
Sandoz said the Hyrimoz launch will be supported by a patient support program to aid with reimbursement navigation, financial assistance, administrative support, and education about the use of biosimilars.
For more information about adalimumab biosimilars and market trends, click here.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
